Top

Annals of Hematology

Published in:

01-06-2019 | Systemic Lupus Erythematosus | Letter to the Editor

Inhibitor eradication in refractory acquired hemophilia with lenalidomide

Authors: C. Pfrepper, W. Poenisch, M. Pierer, M. Metze, T. Kaiser, S. Petros

Published in: Annals of Hematology | Issue 6/2019

Excerpt

Dear Editor, …

Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kuhne A, Gottstein S, Geisen U, Schenk J, Scholz U, Schilling K, Neumeister P, Miesbach W, Manner D, Greil R, von Auer C, Krause M, Leimkuhler K, Kalus U, Blumtritt JM, Werwitzke S, Budde E, Koch A, Knobl P (2015) Prognostic factors for remission of and survival in acquired hemophilia A (AHA). Results from the GTH-AH 01/2010 study. Blood 125(7):1091–1097. https://doi.org/10.1182/blood-2014-07-587089 CrossRefPubMedPubMedCentral

Collins P, Baudo F, Knoebl P, Levesque H, Nemes L, Pellegrini F, Marco P, Tengborn L, Huth-Kuhne A, on behalf of the EACH2 registry collaborators (2012) Immunosuppression for acquired hemophilia A. Results from the European Acquired Haemophilia Registry (EACH2). Blood 120(1):47–55. https://doi.org/10.1182/blood-2012-02-409185 CrossRefPubMedPubMedCentral

Brás GP, Pinto RJSM, Carvalho MMMC, Fernandes S, Andrade J, Guimarães J (2017) Bortezomib. Potential key role in the treatment of multiple myeloma-related acquired hemophilia a. Semin Thromb Hemost 43(1):109–112. https://doi.org/10.1055/s-0036-1597648 CrossRefPubMed

McFadyen JD, Tran H, Kaplan ZS (2017) Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A. Br J Haematol 178(6):986–987. https://doi.org/10.1111/bjh.14185 CrossRefPubMed

Pellom ST, Dudimah DF, Thounaojam MC et al (2015) Modulatory effects of bortezomib on host immune cell functions. Immunotherapy 7(9):1011–1022. https://doi.org/10.2217/imt.15.66 CrossRefPubMed

Ratnasingam S, Walker PA, Tran H, Kaplan ZS, McFadyen JD, Tran H, Teh TC, Fleming S, Catalano JV, Chunilal SD, Johnston A, Opat SS, Shortt J (2016) Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv 1(1):31–35. https://doi.org/10.1182/bloodadvances.2016001412 CrossRefPubMedPubMedCentral

Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74(7):1474–1478. https://doi.org/10.1136/annrheumdis-2014-206016 CrossRefPubMed

Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH (2012) Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 64(2):493–503. https://doi.org/10.1002/art.33333 CrossRefPubMedPubMedCentral

Neuber B, Dai J, Waraich WA, Awwad MHS, Engelhardt M, Schmitt M, Medenhoff S, Witzens-Harig M, Ho AD, Goldschmidt H, Hundemer M (2017) Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells. Oncotarget 8(58):98200–98214. https://doi.org/10.18632/oncotarget.21516 CrossRefPubMedPubMedCentral

10.

Zhang L, Bi E, Hong S, Qian J, Zheng C, Wang M, Yi Q (2015) CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma. Oncotarget 6(34):36032–36040. https://doi.org/10.18632/oncotarget.5506 CrossRefPubMedPubMedCentral

11.

Balaian E, Schuster C, Schönefeldt C, Germing U, Haase D, Tuve S, Ordemann R, Ehninger G, Bornhäuser M, Oelschlaegel U, Mohr B, von Bonin M, Platzbecker U, Wermke M (2016) Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q. Ann Hematol 95(11):1805–1810. https://doi.org/10.1007/s00277-016-2775-y CrossRefPubMed

12.

Lopez-Millan B, La Diaz de Guardia R, Roca-Ho H, García-Herrero CM, Lavoie JR, Rosu-Myles M, Gonzalez-Rey E, O'Valle F, Criado G, Delgado M, Menendez P (2017) Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Exp Mol Med 49(2):e290. https://doi.org/10.1038/emm.2016.143 CrossRefPubMedPubMedCentral

13.

Wu EY, Schanberg LE, Wershba EC, Rabinovich CE (2017) Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus. Lupus 26(6):646–649. https://doi.org/10.1177/0961203316676377 CrossRefPubMed

14.

Montefusco V, Galli M, Spina F, Stefanoni P, Mussetti A, Perrone G, de Philippis C, Dalto S, Maura F, Bonini C, Rezzonico F, Pennisi M, Roncari L, Soldarini M, Dodero A, Farina L, Cocito F, Caprioli C, Corradini P (2014) Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma. Selective occurrence after lenalidomide. Leuk Lymphoma 55(9):2032–2037. https://doi.org/10.3109/10428194.2014.914203 CrossRefPubMed

15.

Loree JM, Cai E, Sheffield BS, Dutz JP, Villa D, Shepherd LE, Connors JM, Sehn LH, Savage KJ (2017) Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. Leuk Lymphoma 58(3):711–714. https://doi.org/10.1080/10428194.2016.1204657 CrossRefPubMed

16.

Saburi M, Ohtsuka E, Itani K, Nagamatsu K, Ikebe T, Miyazaki Y, Ogata M, Saburi Y (2015) Development of acquired hemophilia a during treatment of multiple myeloma with lenalidomide. Rinsho Ketsueki 56(5):496–500. https://doi.org/10.11406/rinketsu.56.496 CrossRefPubMed

17.

Braga WMT, da Silva BR, de Carvalho AC et al (2014) FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunol Immunother 63(11):1189–1197. https://doi.org/10.1007/s00262-014-1589-9 CrossRefPubMedPubMedCentral

18.

Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft AJ, Owen RG, Selby PJ, Cook G (2009) CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(−)CD8(−)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 144(5):686–695. https://doi.org/10.1111/j.1365-2141.2008.07530.x CrossRefPubMed

19.

Saurwein-Teissl M, Lung TL, Marx F, Gschosser C, Asch E, Blasko I, Parson W, Bock G, Schonitzer D, Trannoy E, Grubeck-Loebenstein B (2002) Lack of antibody production following immunization in old age. Association with CD8+CD28- T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 168(11):5893–5899. https://doi.org/10.4049/jimmunol.168.11.5893 CrossRefPubMed

Title: Inhibitor eradication in refractory acquired hemophilia with lenalidomide
Authors: C. Pfrepper
W. Poenisch
M. Pierer
M. Metze
T. Kaiser
S. Petros
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keywords: Systemic Lupus Erythematosus
Multiple Myeloma
Azathioprine
Rituximab
Hemophilia
Rituximab
Azathioprine
Prednisolone
Published in: Annals of Hematology / Issue 6/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-019-03620-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Inhibitor eradication in refractory acquired hemophilia with lenalidomide

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2019

Primary hepatic marginal B cell lymphoma of mucosa-associated lymphoid tissue (MALT) and non-alcoholic steatohepatitis (NASH): more than a coincidence?

The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study

Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin’s lymphoma patients

Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory marginal zone lymphoma

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study

Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page